S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
AMC   40.01 (+0.08%)
NYSEAMERICAN:SYN

Synthetic Biologics Stock Forecast, Price & News

$0.49
+0.01 (+2.06 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.48
$0.51
50-Day Range
$0.32
$0.50
52-Week Range
$0.26
$1.70
Volume1.31 million shs
Average Volume9.48 million shs
Market Capitalization$65.30 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85
30 days | 90 days | 365 days | Advanced Chart
Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for Synthetic Biologics and its competitors with MarketBeat's FREE daily newsletter.


Synthetic Biologics logo

About Synthetic Biologics

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.66 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

Is Synthetic Biologics a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Synthetic Biologics stock.
View analyst ratings for Synthetic Biologics
or view top-rated stocks.

What stocks does MarketBeat like better than Synthetic Biologics?

Wall Street analysts have given Synthetic Biologics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Synthetic Biologics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 23,800 shares, an increase of 28.0% from the August 15th total of 18,600 shares. Based on an average trading volume of 2,060,000 shares, the short-interest ratio is presently 0.0 days. Currently, 0.0% of the company's shares are sold short.
View Synthetic Biologics' Short Interest
.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Tuesday, November 9th 2021.
View our earnings forecast for Synthetic Biologics
.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) announced its quarterly earnings results on Thursday, August, 5th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.01.
View Synthetic Biologics' earnings history
.

How has Synthetic Biologics' stock price been impacted by Coronavirus?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SYN shares have increased by 37.4% and is now trading at $0.4945.
View which stocks have been most impacted by COVID-19
.

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics shares reverse split on Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for SYN?

1 brokerages have issued 12-month price objectives for Synthetic Biologics' stock. Their forecasts range from $2.50 to $2.50. On average, they anticipate Synthetic Biologics' share price to reach $2.50 in the next year. This suggests a possible upside of 405.6% from the stock's current price.
View analysts' price targets for Synthetic Biologics
or view top-rated stocks among Wall Street analysts.

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Steven A. Shallcross, CEO, CFO, Secretary, Treasurer & Director
  • Michael Kaleko, Senior Vice President-Research & Development
  • Vincent I. Perrone, Director-Communication

What other stocks do shareholders of Synthetic Biologics own?

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

Who are Synthetic Biologics' major shareholders?

Synthetic Biologics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Geode Capital Management LLC (0.72%), State Street Corp (0.36%), Virtu Financial LLC (0.19%), Blair William & Co. IL (0.13%), MSD Partners L.P. (0.09%) and Bridgeway Capital Management LLC (0.06%).
View institutional ownership trends for Synthetic Biologics
.

Which major investors are selling Synthetic Biologics stock?

SYN stock was sold by a variety of institutional investors in the last quarter, including MSD Partners L.P., Virtu Financial LLC, and Bridgeway Capital Management LLC.
View insider buying and selling activity for Synthetic Biologics
or view top insider-selling stocks.

Which major investors are buying Synthetic Biologics stock?

SYN stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Blair William & Co. IL, and Geode Capital Management LLC.
View insider buying and selling activity for Synthetic Biologics
or or view top insider-buying stocks.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.49.

How much money does Synthetic Biologics make?

Synthetic Biologics has a market capitalization of $65.30 million.

How many employees does Synthetic Biologics have?

Synthetic Biologics employs 10 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

Where are Synthetic Biologics' headquarters?

Synthetic Biologics is headquartered at 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at (301) 417-4364 or via email at [email protected].


This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.